With the first half of the year behind us, let us reflect on the state of the analytical and life science instrumentation and lab products market, how it has developed thus far and what is in store for the rest of 2015. The original January forecast (see IBO 1/15/15) was published without the benefit of […]
This month, Eurostat released its annual yearbook, which included data on R&D expenditure and personnel for the continent from 2004 to 2013. The figures showed growth in both investment in R&D and the numbers of researchers over the years covered, and provided information on researcher numbers and R&D expenditures by sector. The data suggest that […]
For only the second time in five years, median R&D spending for 22 major publicly held analytical instrument and lab product companies (see table, page 6) climbed at a faster rate than revenues. In 2014, the companies’ median R&D spending advanced 7.3%, while sales grew 5.2%. Consequently, total R&D spending as a percentage of sales […]
Since IBO’s article on federal R&D obligations from fiscal 2013 (FY13) to FY15 (see IBO 6/15/15), the NSF has released additional and more detailed tables on funding. The tables include information on obligations for individual departments within agencies, such as obligations by performer. The table below lists nine federal agencies and departments that are major […]
Company Announcements Fluidigm named Steven C. McPhail as general manager of its Production Genomics Business in May. He previously served as president and CEO of Expression Analysis. The company also announced its plans to register as a medical device manufacturer with the US FDA, list certain of its products as FDA Class 1 devices and […]
Currency and US Demand Drive Biotage Sales First quarter sales for Biotage jumped 26.8%, 6.1% excluding currency, to SEK 144.2 million ($17.3 million = SEK 8.34 = $1). Sales were driven by double-digit growth for sample preparation products as the company introduced the Extrahera system. The new system is freely available to customers agreeing to […]
The latest IBO feature on new sources of R&D funding focuses on June announcements involving sales opportunities for companies producing instruments and lab products. The US government has revealed that more than $4 billion has been contributed by foundations, institutional investors, universities and other donors to the Clean Energy Investment Initiative. A group of long-term […]
For fiscal 2015, the Turkish government’s preliminary R&D allocations totaled TRY 5,850 million ($2,140 million), rising 4.3%. Indirect R&D support (tax incentives, exemptions, reductions in wage taxes for R&D workers and social security contributions) were projected at TRY 1,491 million, up 9.6%. At 40%, R&D from General University Funds (GUF) for “general advancement of knowledge” […]
The 2013 market for prescription and over-the-counter drugs in Africa was $20.8 billion, more than quadrupling since 2003. One of the fastest-growing regions globally, the continent is expected to increase its GDP by 37% to $3.3 trillion between 2013 and 2020. Its pharmaceutical market is estimated to grow total $40–$60 billion by 2020, with a […]
In the US, Europe, Australia and Canada, 2014 biotech sales totaled $123.1 billion, rising 24.3%, with each country or region accounting for 76%, 19%, 5% and 0.2% of sales, respectively. Sales of Gilead Science’s hepatitis C drugs accounted for a sizable portion of revenues in 2014; adjusting for Gilead, growth for the industry was 12%. […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
